Appointment of New Chief Executive Officer

                  Appointment of New Chief Executive Officer

  PR Newswire

  ALCESTER, England, January 8, 2014

ALCESTER, England, January 8, 2014 /PRNewswire/ --

Quanta Fluid Solutions Ltd, a pioneering medical devices company that is
developing advanced haemodialysis systems for patient self-care and dialysis
centres, today announces the appointment of John E. Milad as Chief Executive

John's career spans twenty years, with extensive experience leading and
working with international healthcare companies as an executive manager, board
member, private equity investor and corporate financier, with a strong focus
on emerging medical technologies. Leading up to his appointment, John served
as a Non-Executive Director to Quanta for four years following the initial
investment in the company he led at NBGI Ventures ("NBGI"), a leading venture
capital fund investing in medical technology companies. 

As an Investment Director at NBGI, John was also closely involved-both as a
board member and a venture investor-with a number of other innovative medtech
companies such as Cellnovo Ltd (UK), Symetis SA (Switzerland), Advanced
Cardiac Therapeutics Inc (US), and BoneSupport (Sweden). In this role, John
was involved in a range of finance, strategy, business development and
operational matters, guiding these emerging companies through regulatory
approvals and commercialisation for new medical products. John is a graduate
of the University of Chicago. He currently sits on the i4i selection panel for
the NHS National Institute for Health Research and is a regular speaker and
panellist at various global medtech and investment conferences, including the
Economist Pharma Summit in London in 2014.

Commenting upon his appointment as Chief Executive Office of Quanta, John E.
Milad said: "I am delighted to lead Quanta as the Company enters its next
phase of development, when we will soon obtain CE Mark and then commence
market introduction for our first product. The forthcoming year promises to be
one of great strategic and operational importance, as we initiate the clinical
launch of our unique high-performance, portable, cartridge-based dialysis

"I am particularly excited about the path ahead for Quanta. Our technology
shows great promise to help millions of renal patients around the world to
enjoy a better quality of life by enabling and supporting a broad range of
dialysis modalities across the full continuum of care, from the clinic to the

Johan de Ruiter, Chairman of Quanta, added: "The Board is delighted to welcome
John as Quanta's new CEO. We have known John for many years as a Director of
the Company and, as a healthcare expert, he has been instrumental in helping
us to develop Quanta operationally and strategically. John has valuable
experience with commercialisation of innovative medical devices and I am
therefore extremely confident that he will lead Quanta towards delivering
significant benefits to patients, healthcare providers and payors across the

"I would also like to thank Martin Johnson, our departing CEO and founder, for
all the hard work and dedication he has shown to Quanta. His original idea and
engineering skills have led to a break-through innovation in dialysis. We
look forward to being able to continue to use his expertise and support as the
company transitions to its next phase."

About Quanta

Quanta is a pioneering UK-based medical devices company focusing on the
development and commercialisation of a novel cartridge-based haemodialysis
system designed to be broadly used across the full continuum of care, both in
the clinic and at home. Quanta's system uniquely combines the advantages of a
portable, easy-to-use system with the high performance and flexibility of
larger clinical machines. Quanta is privately owned and based in Alcester,
UK. Quanta was founded in 2008 as a spin-out from IMI plc, with funding led
by a group of venture capital investors specialised in the life sciences:
NBGI, Seroba Kernel, Wellington Partners and BrainsToVentures.

About End Stage Renal Disease and Haemodialysis:

Lifestyle choices, modern diet and increased life expectancy are all
negatively impacting renal health across the globe. End Stage Renal Disease
affects millions of patients worldwide. Haemodialysis is a lifesaving
treatment delivered to an estimated 2 million people globally-with this figure
expected to double in the next decade. At present, haemodialysis is primarily
provided by specialist clinics and centres. Issues of patient benefit, cost
and clinic capacity are driving the growth of home and self-care modalities of
haemodialysis. A number of studies have shown that 30-40% of patients would be
capable of performing self-dialysis (compared with current practice in most
western countries, where very few haemodialysis patients have this option) and
that more frequent and longer dialysis improves health, longevity and quality
of life. A major factor limiting the growth of self-care and home
haemodialysis is the lack of convenient, portable and easy-to-use dialysis
systems. Quanta's haemodialysis system addresses this market need while at the
same time saving set-up and nursing time when used in-centre.

For more information about Quanta, please contact: Quanta John E. Milad, Chief
Executive Officer T: +44(0)1789-400043 E: Consilium
Strategic Communications Amber Bielecka/ Mary-Jane Elliott/ Matthew Neal/
Lindsey Neville T: +44(0)20-7920-2354 E:
Press spacebar to pause and continue. Press esc to stop.